Bristol Myers Rolls Out Long-Term Data For Mavacamten In Heart Disease

  • Bristol Myers Squibb & Co BMY has announced long-term data from a mavacamten study acquired via a $13 billion MyoKardia buyout. 
  • Heart patients who received mavacamten in a cohort of the long-term MAVA-LTE study saw significant reductions in median levels of a hormone called NT-proBNP (58% at week 24 and 67% at week 48).
  • Bristol Myers called this a “sustained reduction,” adding that improvements in left ventricular relaxation and diastolic function were also seen. However, no significant changes were observed in left-ventricular stroke volume.
  • Mavacamten was “well-tolerated” in the long-term study, Bristol Myers said. However, nine patients paused their treatment because left ventricular ejection fractions were too low. 
  • Eight of them resumed treatment at a lower dose after recovery, while one discontinued the trial permanently.
  • Price Action: BMY shares closed at $59.43 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsHeart Failure
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!